The Trump administration made a controversial move over the weekend by terminating employees at the Food and Drug Administration (FDA), according to sources. The exact number of FDA employees affected by the layoffs was not immediately clear, but it was reported that some of those let go worked in the FDA’s Center for Devices and Radiological Health.
This action was part of a wider purge of probationary employees that began on Friday, which also impacted staff at the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). Reports indicated that a total of 5,200 probationary employees across the Department of Health and Human Services, which includes the FDA, NIH, and CDC, were set to lose their jobs.
The CDC was expected to see around 1,300 workers affected by the layoffs, and contract workers across HHS have also been let go in recent weeks. The Trump administration, with the assistance of Elon Musk’s U.S. DOGE Service, has been actively reducing the federal workforce since the President’s inauguration in January. Federal employees have been encouraged to leave through buyout offers, return-to-work orders, and the threat of limited legal protections.
It is worth noting that President Trump’s nominee to lead the FDA, Marty Makary, has not yet been confirmed by the Senate, leaving Sara Brenner as the agency’s acting commissioner. Reports on social media from independent journalists and analysts also confirmed the staff cuts at the FDA.
The FDA, a crucial agency that regulates products such as foods, medicines, and medical devices, employs nearly 20,000 people. The impact of these layoffs on FDA-regulated products and the review process for drugs and medical products has raised concerns among investors in biotechnology, pharmaceutical, and medical device companies. The fear is that if employees paid partially by “user fees” are cut, it could lead to delays in product reviews and potentially affect stock prices.
As the situation unfolds, it remains to be seen how these layoffs will impact the operations of the FDA and the broader healthcare industry. The fallout from these actions could have far-reaching implications for public health and the regulation of essential products.
